CHUV
Les activités du CHUV
MENU
Service de gastro-entérologie
et d’hépatologie
Accueil > Recherche > Publications > 2012

Publications


Articles originaux et de revue


2012

1: Bochud P-Y, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, Goossens N, Kuske L, Müllhaupt B, Gerlach TJ, Heim MH, Moradpour D, Cerny A, Malinverni R, Regenass S, Dollenmaier G, Hirsch H, Martinetti G, Gorgievski M, Bourlière M, Poynard T, Theodorou I, Abel L, Pol S, Dufour J-F, Negro F, on behalf of the Swiss Hepatitis C Cohort Study Group.
    IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes
Hepatology 2012;55:384-394
2: Buyse S, Roque AM, Vaghefi Parissa, Gigou M, Dussaix E, Duclos-Vallée JC, Samuel D, Guettier C.
    Acute hepatitis with periportal confluent necrosis associated with human herpes virus 6 infection in liver transplant patients.
Am J Clin Pathol, in press
3: Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L
    Mucosal healing with anti-TNF antibodies.
Digestion 2012;86 Suppl 1:16-22
4: Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Wakita T
    Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone
J Virol 2012;86:10805-10820
5: Date T, Morikawa K, Tanaka Y, Tanaka-Kaneko K, Sata T, Mizokami M, Wakita T
    Replication and infectivity of a novel genotype 1b hepatitis C virus clone
Microbiol Immunol 2012;56:308-317
6: Esser-Nobis K, Romero-Brey I, Ganten TM, Gouttenoire J, Harak C, Klein R, Schemmer P, Binder M, Schnitzler P, Moradpour D, Bartenschlager R, Polyak SJ, Stremmel W, Penin F, Eisenbach C, Lohmann V
    Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B
Hepatology
7: European Association for the Study of the Liver Clinical Practice Guidelines:
    Wilson's disease
J Hepatol 2012;56:671-685
8: Feagan BG, Lémann M, Befrits R, Connell W, D'Haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg M, Sorrentino D, van der Woude CJ, Vermeire S, Rutgeerts P
    Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.
Inflamm Bowel Dis 2012;18:152-160
9: Felley C, Bouzourene H, VanMelle MB, Hadengue A, Michetti P, Dorta G, Spahr L, Giostra E, Frossard JL
    Age, smoking and overweight contribute to the development of intestinal metaplasia of the cardia
World J Gastroenterol 2012;18:2076-2083
10: Fraga M, Godat S, Nydegger A, Moradpour D, Schoepfer AM
    Fecal calprotectin: a diagnostic tool for inflammatory bowel disease.
Rev Med Suisse 2012;8:1669-1673
11: Gencer B, Moradpour D, Rodondi N
    Traitement des dyslipidémies et atteinte hépatique.
Rev Med Suisse 2012;8:507-512
12: Girardin F, Daali Y, Gex-Fabry M, Rebsamen M, Roux-Lombard P, Cerny A, Bihl F, Binek J, Moradpour D, Negro F, Desmeules J, and the Swiss Hepatitis C Cohort Study Group
    Liver kidney microsomal type 1 antibodies reduce CYP2D6 activity in patients with chronic hepatitis C virus infection
J Viral Hepat 2012;19:568-573
13: Girardin M, Manz M, Manser C, Biedermann L, Wanner R, Frei P, Safroneeva E, Mottet C, Rogler G, Schoepfer AM
    First-line therapies in inflammatory bowel disease.
Digestion 2012;86 Suppl 1:6-10
14: Godat S, Antonino AT, Dehlavi M-A, Moradpour D, Doerig C.
    Hypertension portale et prise en charge de l'ascite.
Rev Med Suisse 2012;8:1665-1668
15: Hadengue A and Moradpour D.
    La maladie alcoolique du foie : un autre maladie négligée ? [Editorial].
Rev Med Suisse 2012;8:1643-1644
16: Inokuchi M, Ito T, Nozawa H, Miyashita M, Morikawa K, Uchikoshi M, Shimozuma Y, Arai J, Shimazaki T, Hiroishi K, Imawari M
    Lymphotropic hepatitis C virus has an interferon-resistant phenotype
J Viral Hepat 2012;19:254-262
17: Kaech C, Pache I, Bürgisser P, Elzi L, Darling KE, Cavassini M
    Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen.
J Infect 2012;65:157-164
18: Kuske L, Mensen A, Müllhaupt B, Negro F, Semela D, Moradpour D, Malé PJ, Heim MH, Malinverni R, Cerny A, Dufour J-F, on behalf of the Swiss Hepatitis C Cohort Study Group.
    Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma.
Swiss Med Wkly 2012;142:w13651
19: Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S
    Treatment of extraintestinal manifestations in inflammatory bowel disease.
Digestion 2012;86 Suppl 1:28-35
20: Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhoop K, Bojunga J, Sarrazin C, Zeuzem S, Müller T, Berg T, Bochud PY, Moradpour D, and the Swiss Hepatitis C Cohort Study Group.
    A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-a-based therapy of chronic hepatitis C.
PLoS One 2012;7:e40159
21: Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, Dufour J-F, Gerlach TJ, Heim MH, Malinverni R, Müllhaupt B, Negro F, Moradpour D, Bochud PY, and the Swiss Hepatitis C Cohort Study Group.
    Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-a and ribavirin therapy.
Hepatology 2012;55:1038-1047
22: Müllhaupt B and Moradpour D.
    Schlaglicht Hepatologie: Wichtiges zur chronischen Hepatitis C.
Schweiz Med Forum, in press
23: Maillard MH, Hiroz P, Wagner D, Prior J, Boubaker A, Pralong F, Dorta G, Nichita C
    Tumeurs neuroendocrines digestives: pléomorphes et souvent ignores.
Rev Med Suisse 2012;8:1658-1663
24: Manuel O, Baid-Agrawal S, Moradpour D, Pascual M.
    Immunosuppression in hepatitis C virus-infected patients after kidney transplantation.
Contrib Nephrol 2012;176:97-107
25: Manz M, Vavricka SR, Wanner R, Lakatos PL, Rogler G, Frei P, Safroneeva E, Schoepfer AM.
    Therapy of steroid-resistant inflammatory bowel disease.
Digestion 2012;86 Suppl 1:11-15
26: Meyrat P, Safroneeva E, Schoepfer AM
    Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.
Aliment Pharmacol Ther 2012;36:1084-93
27: Moradpour D and Penin F.
    Hepatitis C virus proteins: from structure to function.
Top Microbiol Immunol, in press
28: Moradpour D und Blum HE
    Ikterus. In: Siegenthalers Differenzialdiagnose. Innere Krankheiten - vom Symptom zur Diagnose.
Battegay E, Hrsg. 20. Auflage. Georg Thieme Verlag, Stuttgart - New York, 2013, pp. 752-791
29: Moradpour D und Blum HE
    Schmerzen im Bereich des Abdomens. In: Siegenthalers Differenzialdiagnose. Innere Krankheiten - vom Symptom zur Diagnose.
Battegay E, Hrsg. 20. Auflage. Georg Thieme Verlag, Stuttgart - New York, 2013, pp. 272-317.
30: Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Müllhaupt B, Semela D, Dufour JF, Heim MH, Moradpour D, Cerny A, Malinverni R, Hirsch H, Martinetti G, Suppiah V, Stewart G, Booth DR, George J, Casanova JL, Bréchot C, Rice CM, Talal AH, Jacobson IM, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud PY, Abel L; Swiss Hepatitis C Cohort Study Group, International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group.
    Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
Gastroenterology 2012;143:1244-1252
31: Quarato G, Scrima R, Agriesti F, Moradpour D, Capitanio N, Piccoli C.
    Targeting mitochondria in the infection strategy of the hepatitis C virus.
Int J Biochem Cell Biol 2012, in press
32: Quarato G, Scrima R, Gavillet B, Vuagniaux G, Moradpour D, Capitanio N, Piccoli C
    The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction.
Hepatology 2012;55:1333-1343
33: Rau M, Stickel F, Russmann S, Manser C, Becker P, Weisskopf M, Schmitt J, Dill MT, Dufour JF, Moradpour D, Semela D, Müllhaupt B, Geier A.
    Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with hepatitis C virus infection.
J Hepatol, in press
34: Reinisch W, Van Assche G, Befrits R, Connell W, D'Haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg MS, Sorrentino D, van der Woude CJ, Vermeire S, Panes J.
    Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus.
J Crohns Colitis 2012;6:248-258
35: Rieder F, Karrasch T, Ben-Horin S, Schirbel A, Ehehalt R, Wehkamp J, de Haar C, Velin D, Latella G, Scaldaferri F, Rogler G, Higgins P, Sans M
    Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing.
J Crohns Colitis 2012;6:373-385
36: Schaffer T, Flogerzi B, Schoepfer AM, Seibold F, Müller S
    Increased titers of anti-Saccharomyces cerevisiae antibodies in Crohn’s disease patients with reduced H-ficolin levels but normal MASP-2 activity.
J Crohns Colitis, in press
37: Schneider MP, Genre N, Reymermier M, Bugnon O, Moradpour D.
    Hépatite C - Avancées thérapeutiques.
pharmaJournal 11.2012, No 24, pp. 5-9
38: Schoepfer AM, Safroneeva E, Vavricka SR, Peyrin-Biroulet L, Mottet C.
    Treatment of fibrostenotic and fistulizing Crohn's disease.
Digestion 2012;86 Suppl 1:23-27
39: Schoepfer AM, Vavricka SR, Zahnd-Straumann N, Straumann A, Beglinger C
    Monitoring inflammatory bowel disease: clinical activity is judged to be more relevant than endoscopic severity or biomarkers.
J Crohns Colitis 2012;6:412-418
40: Straumann A, Aceves SS, Blanchard C, Collins MH, Furuta GT, Hirano I, Schoepfer AM, Simon D, Simon HU.
    Pediatric and adult eosinophilic esophagitis: similarities and differences.
Allergy 2012;67:477-90
41: Swiss Association for the Study of the Liver (corresponding author)
    Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir (Expert Opinion Statement).
Swiss Med Wkly 2012;142:w13516
42: Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM, Swiss IBD Cohort Study Group
    Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease.
Inflamm Bowel Dis 2012;18:496-505
43: Wölk B, Trautwein C, Büchele B, Kersting N, Blum HE, Rammensee H-G, Cerny A, Stevanovic S, Moradpour D*, Brass V*. (*joint last authors)
    Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands.
PLoS One 2012;7:e29286
44: Wenger S, Nikolaus S, Howaldt S, Bokemeyer B, Sturm A, Preiss JC, Schoepfer AM, Stallmach A, Schmidt C.
    Predictors for subsequent need of immunosuppressive therapy in early Crohn’s disease.
J Crohns Colitis 2011;6:21-28
45: Wildi SM*, Schoepfer AM*, Vavricka SR, Fruehauf H, Safroneeva E, Wiegand N, Bauerfeind P, Fried M. (*joint first authors)
    Colorectal polypectomy during insertion and withdrawal or only during withdrawal? A randomized controlled trial.
Endoscopy 2012;44:1019-23